Skip to content
2000
Volume 18, Issue 28
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Histone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of HDACs expression, mutation and/or inappropriate recruitments has been discovered in a broad range of tumors contributing to the tumorigenesis through a serial of biological pathways. HDACs, therefore, are characterized as promising cancer therapeutic targets, and their inhibitors are under rapid development. Here, we discuss HDAC inhibitors in terms of their functional mechanism establishing the anti-tumor effects and potential clinical applications including the synergistic effects in combinational treatment.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026619666181210152115
2018-11-01
2025-07-09
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026619666181210152115
Loading

  • Article Type:
    Review Article
Keyword(s): Cancer treatment; DNA; Epigenetics; Histone Deacetylase; Inhibitors; RNA
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test